Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis.

ABSTRACT:

Background/objectives

Patients with systemic vasculitis faced the risk of severe COVID-19 and high mortality during the pandemic. Although SARS-CoV-2 vaccination mitigates these outcomes, vaccine hesitancy persists, and data on immunogenicity and safety in vasculitis is still limited. This study aims to assess response to primary and booster doses of SARS-CoV-2 vaccination in systemic vasculitis.

Methods

This multicenter cohort study including systemic vasculitis included patients from SAFER study (Safety and Efficacy of COVID-19 Vaccines in Rheumatic Diseases). We evaluated serum IgG levels against the SARS-CoV-2 spike protein receptor-binding domain (IgG anti-RBD) at baseline and 28 days post-vaccination, disease activity scores, new cases of COVID-19 infections, and adver

SUBMITTER: Biegelmeyer E 

PROVIDER: S-EPMC12665670 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature